Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3509446 | 1.00 | S1PR1 (0.55) | S1PR1S1PR4S1PR3S1PR5FFAR1 | |
| SCHEMBL14539807 | 0.96 | S1PR1 (0.57) | S1PR1S1PR4S1PR3S1PR5FFAR1 | |
| SCHEMBL3509437 | 0.95 | S1PR1 (0.59) | S1PR1S1PR4S1PR3S1PR5FFAR1 | |
| SCHEMBL3511037 | 0.95 | S1PR1 (0.59) | S1PR1S1PR4S1PR3S1PR5FFAR1 | |
| Hydrochloric Acid SCHEMBL7621155 | 0.95 | S1PR1 (0.56) | S1PR1S1PR4S1PR3S1PR5FFAR1 | |
| SCHEMBL3508183 | 0.93 | S1PR1 (0.52) | S1PR1S1PR4S1PR3S1PR5FFAR1 | |
| SCHEMBL3507822 | 0.93 | S1PR1 (0.52) | S1PR1S1PR4S1PR3S1PR5FFAR1 | |
| SCHEMBL1912503 | 0.93 | S1PR1 (0.56) | S1PR1S1PR4S1PR3S1PR5FFAR1 | |
| SCHEMBL6036008 | 0.93 | S1PR1 (0.56) | S1PR1S1PR4S1PR3S1PR5FFAR1 | |
| Hydrochloric Acid SCHEMBL688656 | 0.92 | S1PR1 (0.55) | S1PR1S1PR4S1PR3S1PR5FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4012823-B2 | — | — | 2007-11-21 | — | — | JP | claimed |
| EP-1377593-B1 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-12-28 | — | — | EP | claimed |
| JP-2004531501-A | — | — | 2004-10-14 | — | — | JP | claimed |
| US-20040147490-A1 | 2-Amino-propanol derivatives | ALBERT RAINER (CH) | 2004-07-29 | — | — | US | claimed |
| EP-1377593-A2 | 2-AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | claimed |
| WO-2002076995-A2 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | claimed |
| EP-2045325-B1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO CO LTD (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| EP-1915994-A1 | CYCLIC AMINE DERIVATIVE CONTAINING PPAR REGULATOR | Sankyo Company, Limited (JP) | 2008-04-30 | — | — | EP | disclosed |
| US-7326801-B2 | 2-amino-propanol derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| US-7326801-B2 | 2-amino-propanol derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| US-7326801-B2 | 2-amino-propanol derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| EP-1377593-B1 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20040147490-A1 | 2-Amino-propanol derivatives | ALBERT RAINER (CH) | 2004-07-29 | — | — | US | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | PPARG, PPARA, PPARD | S1PR1 282/4885S1PR4 739/4885S1PR3 281/4885 |
| US-20040147490-A1 | 2-Amino-propanol derivatives | CD4, HLA-DRB1, CCR1 | S1PR1 525/4885S1PR4 1260/4885S1PR3 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.